CanniMed Therapeutics (TSX: CMED) priced its initial public offering at $12, selling 5mm shares through a syndicate led by AltaCorp Capital to raise $60mm. The underwriters, which also included ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback